Genmab/$GMAB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Ticker
- $GMAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,119
- Headquarters
- Copenhagen, Denmark
- Website
- www.genmab.com
Genmab Metrics
BasicAdvanced
$33B
4.59
$11.69
0.52
-
Price and volume
Market cap
$33B
Beta
0.52
52-week high
$59.97
52-week low
$23.62
Average daily volume
6M
Financial strength
Current ratio
2.454
Quick ratio
2.431
Long term debt to equity
0.766
Total debt to equity
0.821
Interest coverage (TTM)
3.49%
Profitability
EBITDA (TTM)
1,356
Gross margin (TTM)
92.67%
Net profit margin (TTM)
16.97%
Operating margin (TTM)
30.63%
Effective tax rate (TTM)
6.30%
Revenue per employee (TTM)
$1,380,000
Management effectiveness
Return on assets (TTM)
8.24%
Return on equity (TTM)
12.07%
Valuation
Price to earnings (TTM)
4.587
Price to revenue (TTM)
0.767
Price to book
35.25
Price to tangible book (TTM)
-77.95
Price to free cash flow (TTM)
3.911
Free cash flow yield (TTM)
25.57%
Free cash flow per share (TTM)
13.712
Growth
Revenue change (TTM)
11.71%
Earnings per share change (TTM)
-53.42%
3-year revenue growth (CAGR)
18.82%
10-year revenue growth (CAGR)
34.46%
3-year earnings per share growth (CAGR)
6.81%
10-year earnings per share growth (CAGR)
20.40%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Analyst projections of the future price of Genmab stock.
Bulls say / Bears say
Revenue rose 25% year on year in the first half of 2026, and Genmab raised its full-year revenue outlook to $4.33–$4.53 billion. That points to strong near-term trading and improved expectations. (Genmab)
Genmab is building growth beyond DARZALEX: first-half EPKINLY/TEPKINLY sales rose 48%, while royalties from Kesimpta rose 31%. These gains add momentum from other products to the royalty base. (Genmab)
Recent late-stage results strengthen Genmab’s pipeline case: Rina-S showed significant improvements in progression-free and overall survival, and petosemtamab’s combination showed significant overall-survival and response improvements in first-line head and neck cancer. (Genmab)
DARZALEX royalties face a steep patent-driven decline: its US patents expire in 2029, and an analyst cited by BioSpace estimates Genmab’s DARZALEX revenue could fall from about $3.3 billion in 2028 to below $1 billion by 2031. (BioSpace)
The Merus acquisition has left Genmab with substantial financing costs: first-half results included $174 million of interest expense and $43 million of debt-fee amortisation on borrowings used to fund the deal. Higher development and launch spending adds pressure while the company pursues growth. (SEC)
Positive trial data still need to translate into approvals and sales to replace lost DARZALEX royalties. BioSpace reports that Genmab faces a highly competitive market and must prove it can commercialise key assets successfully. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Upcoming events
No upcoming events
Genmab News
AllArticlesVideos
Funds containing Genmab
Fund name | Fund size | $GMAB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.34% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.